Atea Pharmaceuticals, Inc. (AVIR) Financials
AVIR Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 595.0 million | 39.8 million |
2023-09-30 | 608.1 million | 26.3 million |
2023-06-30 | 626.0 million | 23.7 million |
2023-03-31 | 638.1 million | 19.9 million |
AVIR Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -21.8 million | 12.2 million |
2023-09-30 | -17.6 million | 12.4 million |
2023-06-30 | -16.1 million | 12.4 million |
2023-03-31 | -29.9 million | 12.5 million |
AVIR Net Income
No data available :(
AVIR Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 578.1 million | - | 2.4 million |
2023-09-30 | 595.1 million | - | 2.6 million |
2023-06-30 | 608.1 million | - | 2.8 million |
2023-03-31 | 620.5 million | - | 2.9 million |
AVIR Shares Outstanding
AVIR Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | - | 35.0 million | 11.5 million | 104000 |
2023-09-30 | - | 28.2 million | 12.6 million | - |
2023-06-30 | - | 22.1 million | 13.2 million | - |
2023-03-31 | - | 29.0 million | 12.6 million | - |
AVIR Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | 104000 |
2023-09-30 | - | 104000 |
2023-06-30 | - | 104000 |
2023-03-31 | - | 104000 |
AVIR
Price: $3.71
52 week price:
Earnings Per Share: -1.63 USD
P/E Ratio: -2.56
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 884000
Ebitda: -17.0 millionMarket Capitalization: 316.9 million